№ lp_1_2_26859
File format: docx
Character count: 44346
File size: 113 KB
Year:
2025
Region / City:
Great Britain
Theme:
Carbon Capture Utilisation and Storage, Offshore Hydrogen Production, Health and Safety
Document Type:
Consultative Document
Organization / Institution:
Health and Safety Executive (HSE)
Author:
Health and Safety Executive
Target Audience:
Stakeholders in health and safety, energy, and environmental sectors
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Contextual description:
A consultative document issued by the Health and Safety Executive (HSE) regarding regulatory proposals for offshore hydrogen production, CCUS operations, and related transportation safety measures.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region / City:
Not specified
Theme:
Organ Utilisation, Transplantation
Document Type:
Role Description
Organization / Institution:
NHSBT
Author:
Not specified
Target Audience:
Healthcare professionals, Trusts/Boards, Clinical Leads for Organ Donation
Period of Action:
Up to three years, with possibility of extension
Approval Date:
November 2024
Date of Changes:
Not specified
Year:
2024
Region / City:
Australia
Theme:
Pharmaceutical benefits, Chronic myeloid leukaemia (CML) treatment
Document type:
Research analysis
Organization / Institution:
Drug Utilisation Sub-Committee (DUSC)
Author:
Drug Utilisation Sub-Committee (DUSC)
Target audience:
Healthcare professionals, policymakers, pharmaceutical industry
Period of validity:
From March 2022 onward
Approval date:
October 2024
Date of changes:
March 2022
Year:
2020
Country:
Australia
Subject:
Osteoporosis pharmacotherapy
Focus medicine:
Denosumab
Other medicines included:
Bisphosphonates, raloxifene, teriparatide, strontium ranelate, calcitriol
Type of document:
Drug utilisation analysis report
Data sources:
Pharmaceutical Benefits Scheme (PBS) data, MedicineInsight data
Committee:
Drug Utilisation Sub-Committee (DUSC)
Study design:
Retrospective cohort analysis
Population:
Patients aged 50 years and over
Study period:
January 2012 – June 2019 (PBS); January 2014 – December 2017 (MedicineInsight cohorts)
Geographic scope:
National
Health system context:
Pharmaceutical Benefits Scheme
Contextual description:
Analytical health policy report examining national prescribing patterns, initiation, discontinuation, and subsequent therapy use of denosumab and other osteoporosis medicines based on linked administrative and general practice data.
Year:
2016
Region / City:
Zambia
Subject:
Constituency Development Fund Management
Document Type:
Guidelines
Organization / Institution:
Research Public and International Relations Department
Author:
Not specified
Target Audience:
Members of Parliament of Zambia
Period of Validity:
Not specified
Approval Date:
December, 2016
Date of Changes:
Not specified
Year:
2021
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Committee:
Drug Utilisation Sub-Committee (DUSC)
Meeting Number:
103
Location:
Australia
Reviewed Medicines:
Golimumab, Nivolumab plus Ipilimumab, Pembrolizumab, Bictegravir+emtricitabine+tenofovir alafenamide, Dolutegravir+rilpivirine, Tolvaptan
Purpose:
Analysis of medicine utilisation and reporting to PBAC
Data Period:
Up to 31 July 2021
Type of Document:
Meeting report / utilisation review
Contact:
DUSC Secretariat, [email protected]
Chair:
Professor Christopher Etherton-Beer
Year:
2016
Month:
June 2016
Country:
Australia
Topic:
Utilisation of medicines for glaucoma and elevated intraocular pressure
Document type:
Drug utilisation review report
Committee:
Drug Utilisation Sub-Committee (DUSC)
Related programs:
Pharmaceutical Benefits Scheme (PBS); Repatriation Schedule of Pharmaceutical Benefits (RPBS)
Data source:
DUSC and Department of Human Services prescription databases (2004–2015)
Period analysed:
2004–2015
Scope:
PBS-listed single ingredient and fixed dose combination glaucoma medicines
Exclusions:
Acetazolamide excluded from utilisation analysis
Clinical focus:
Open angle glaucoma, ocular hypertension, intraocular pressure reduction
Regulatory authority referenced:
Therapeutic Goods Administration (TGA)
Guideline referenced:
National Health and Medical Research Council Guidelines for the Screening, Prognosis, Diagnosis, Management and Prevention of Glaucoma (2010)
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical benefits scheme, biological disease-modifying anti-rheumatic drugs (bDMARDs), chronic plaque psoriasis
Document Type:
Research report
Organization / institution:
Drug utilisation sub-committee (DUSC)
Author:
Not specified
Target Audience:
Healthcare professionals, policymakers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Country:
India
Issuing Authority:
Government of India, Department of Atomic Energy
Form Title:
BRNS Form – III Utilisation Certificate
Document Type:
Grant Utilisation Certificate Form
Related Schemes:
Research Project / Symposium / Foreign Travel Assistance / Other Schemes
Financial Year:
Specified year(s) of grant
Place of Issue:
Mumbai-400 001
Signatories:
Principal Investigator; Registrar/Head of Institution; Statutory Auditor (Government Auditor)/Chartered Accountant/Internal Auditor
Audit Requirement:
Statutory audit or Chartered Accountant audit; internal audit accepted subject to C&AG audit of institutional accounts
Subject:
Certification of utilisation of Grant-in-aid and surrender or adjustment of unutilised balance
Year:
2023
Region:
Australia
Topic:
Hypercholesterolaemia treatment
Document type:
Drug utilisation analysis
Organization:
Department of Health and Aged Care; Services Australia
Author:
Drug Utilisation Sub-Committee (DUSC)
Target audience:
Healthcare policymakers, clinicians
PBS listing date:
1 December 2016
Data sources:
PBS and Authorities databases
Indications:
Homozygous familial hypercholesterolaemia, heterozygous familial hypercholesterolaemia, non-familial hypercholesterolaemia
Number of patients treated (2021):
6,119
Number of prescriptions supplied (2021):
48,483
Therapeutic class:
PCSK9 inhibitor
Project Title:
Energy Efficient Production and Utilisation of Charcoal through Innovative Technologies and Private Sector Involvement in Sierra Leone
UNDP PIMS Number:
4904
Atlas Project ID:
00090575
GEF Agency:
United Nations Development Programme
Executing Agency:
Ministry of Energy, Republic of Sierra Leone
Focal Area:
Climate Change
Project Period:
2015–2019
Document Type:
Mid-term Review Report
Date of Report:
November 2018
Evaluation Team:
Dr. Arun Rijal (Independent International Consultant); Dr. Hindowa Momoh (Independent National Consultant)
Country:
Sierra Leone
Evaluation Scope:
Project design, implementation, results, sustainability and performance
Annexes Included:
Terms of Reference, Mission Itinerary, Persons Interviewed, Project Indicators, Organizational Structure, Evaluation Criteria
Year:
2021
Region / City:
Australia
Topic:
Drug Utilisation for ADHD
Document Type:
Utilisation Analysis
Organization / Institution:
Drug Utilisation Sub-Committee (DUSC)
Author:
Not specified
Target Audience:
Healthcare professionals, policymakers
Period of Validity:
2014-2020
Approval Date:
June 2021
Date of Changes:
Not specified
Year:
2023
Region / City:
Uttar Pradesh, India
Topic:
Healthcare Utilisation, Education, Private Healthcare
Document Type:
Research Article
Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, policymakers, healthcare professionals
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Keywords:
Healthcare utilisation, Financial accessibility, Out-of-pocket expenditure, Education, Rural Uttar Pradesh, Logistic regression, Principal Component Analysis
Year:
2025
Region / City:
Sub-Saharan Africa
Topic:
HIV self-testing, health services accessibility, HIV diagnosis
Document Type:
Review Article
Institution:
Joanna Briggs Institute
Author:
Not specified
Target Audience:
Researchers, healthcare professionals, policymakers
Period of Effectiveness:
Not specified
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
Australia
Theme:
Medicine utilisation analysis
Document Type:
Meeting minutes
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Professor Christopher Etherton-Beer
Target Audience:
Health policy makers, pharmaceutical industry stakeholders, medical professionals
Period of Validity:
June 2021
Approval Date:
June 2021
Modification Date:
N/A
Year:
2016
Region / city:
Australia
Topic:
Pharmaceutical utilisation / hepatic encephalopathy
Document type:
Analytical report
Organization / institution:
Drug Utilisation Sub-Committee (DUSC), Department of Human Services (DHS)
Author:
DUSC
Target audience:
Healthcare policymakers, clinicians
Period covered:
December 2013 – March 2016
Date of listing:
1 December 2013
Drug:
Rifaximin
Indication:
Prevention of hepatic encephalopathy recurrence
Dosage:
550 mg twice daily
Treatment requirements:
Combination with lactulose if tolerated; prior episodes of HE required
Regulatory authority:
Therapeutic Goods Administration (TGA)
PBS restriction:
Specialist treatment only; telephone authority approval required
Study type:
Retrospective utilisation analysis
Key findings:
Patient numbers higher than predicted; prescriptions per patient lower than estimated; expenditure aligned with second-year projections
Year:
2026
Region / City:
Global
Topic:
Human Rights Council, Mandate Vacancies, Candidate Selection
Document Type:
Report
Body / Institution:
Human Rights Council
Author:
Consultative Group to the President of the Human Rights Council
Target Audience:
Human Rights Council members, international organizations, policy makers
Period of Validity:
2025–2026
Approval Date:
23 January 2026
Date of Changes:
N/A
Contextual Description:
A report outlining the proposed candidates for vacancies in various human rights positions to be filled at the sixty-first session of the Human Rights Council.
Note:
Year
Contextual Description:
A detailed appendix for a Level 5 HR Consultant Partner apprenticeship project, including sections on apprentice details, red/amber components, evidence, and supporting evidence.
Year:
2015
Region / city:
Global
Topic:
Health, Nutrition, and Population
Document type:
Nomination form
Organization / institution:
World Bank Group
Author:
World Bank Group
Target audience:
Civil society organizations and individuals with relevant experience in health, nutrition, and population
Period of validity:
N/A
Approval date:
January 2015
Date of amendments:
N/A
Year:
2015
Region / City:
Richards Bay
Theme:
Port Management
Document Type:
Action Items
Organ / Institution:
Port Consultative Committee
Author:
Secretariat
Target Audience:
Port Users
Period of Validity:
2015/16
Approval Date:
29 July 2015
Amendment Date:
Not specified
Year:
2023
Region / City:
London
Topic:
Finance, Employee Relations, Trade Union Discussions
Document Type:
Meeting Minutes
Organization:
University College London (UCL)
Author:
Anthony Smith (Chair)
Target Audience:
UCL management, staff, trade unions
Effective Period:
26th June 2023
Approval Date:
26th June 2023
Date of Changes:
N/A